Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership

“Our collaboration with CytoSorbents enables us to offer this innovative, easy-to-use blood purification therapy to address our customers’ most challenging cardiac cases,” stated Arik Anderson, President of Perfusion and Surgical Devices Division at Terumo. “CytoSorb integrates with the heart-lung machine platform, giving surgical teams, for the first time, the ability to safely reduce dangerous inflammatory mediators in real-time as they are being generated during cardiac surgery.”

Continue reading

Virtual 7th International CytoSorb Users` Meeting

2020 was a year like no other. Since March 2020 conferences and events have rightfully been cancelled or postponed across the world, including our Annual International CytoSorb Users Meeting. So we challenged ourselves to come up with something that could to some extend replace the live event.

Continue reading

CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022

Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, „I am happy to announce CytoSorbents successfully completed its CE Mark and ISO13485:2016 re-certification audits. These certificates cover CytoSorb and our new manufacturing facility commissioned in June 2018. The success of this renewal of the CE Mark and recent audit is a reflection of CytoSorbents‘ ongoing commitment to quality. I am very proud of our quality, manufacturing, and research teams that contributed to these accomplishments.“

Continue reading